Table 1 Cooper et al.
From: Pathway analysis of genome-wide data improves warfarin dose prediction
Covariate | Mean/% Patients | Standard Deviation | Coefficient | p-value |
|---|---|---|---|---|
Age | 58.7 | 15.7 | -0.0407 | 6.43E-05* |
Weight (lbs) | 195.3 | 45.3 | 0.0109 | 1.32E-03* |
Amiodarone | 14.3% | - | -1.393 | 1.11E-03* |
Losartan | 9.3% | - | -0.420 | 4.14E-01 |
VKORC1 AG | 46.6% | - | 2.157 | 1.03E-05* |
VKORC1 GG | 41.0% | - | 3.821 | 2.78E-13* |
CYP2C9 status | 29.2% | - | -1.330 | 1.77E-04* |
Principal Component 1 | - | 38.8 | -0.000389 | 9.19E-01 |
Principal Component 2 | - | 25.5 | -0.00576 | 3.15E-01 |
A#m Metabolic Pathway | 19.38 | 3.57 | -0.0999 | 2.44E-02* |